ÂÜÀòÂÒÂ×

Daniel joined Sanofi Ventures in 2018. He began his career as a member of Biogen's corporate strategy group. He then joined Bioverativ as a member of their BD organization, most recently as Business Development Lead, where he played an important role in both their acquisition of True North Therapeutics and their research collaboration with Bicycle Therapeutics. Given the recent acquisition, we are fortunate to benefit from Daniel’s expertise in the rare hematology and complement space.

Daniel graduated with honors from Bates College with a Bachelor of Science in Economics and a minor in Chemistry.